Kiovig
Kiovig is a highly purified solution of human normal immunoglobulin (IgG) containing a broad spectrum of antibodies against infectious agents. It is administered intravenously to restore normal IgG levels or to modify immune responses in autoimmune conditions.
Dosage by Body Weight
Dosage must be individualized by a specialist based on clinical response, IgG trough levels, and the specific indication. Replacement therapy typically starts at 0.4 to 0.8 g/kg body weight, followed by maintenance doses every 3 to 4 weeks. Immunomodulation doses are higher, up to 2 g/kg, often divided over 2 to 5 days.
- Body Weight
- Below 5 kg
- Dose
- 0.4 to 0.8 g/kg (approx. 1 to 4 g)
- Frequency
- Every 3 to 4 weeks for replacement therapy
- Tracking Notes
- Administered strictly under clinical supervision in a hospital setting. Start infusion at a very slow rate.
- Body Weight
- 5-7 kg
- Dose
- 2 to 5.6 g (based on 0.4 to 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Doses up to 2 g/kg may be used for immunomodulation, divided over 2 to 5 days. Ensure adequate hydration.
- Body Weight
- 8-10 kg
- Dose
- 3.2 to 8 g (based on 0.4 to 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Monitor renal function and urine output closely during therapy.
- Body Weight
- 11-15 kg
- Dose
- 4.4 to 12 g (based on 0.4 to 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Monitor vital signs continuously during infusion and for at least 20 minutes after completion.
- Body Weight
- 16-20 kg
- Dose
- 6.4 to 16 g (based on 0.4 to 0.8 g/kg)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Infusion rate can be gradually increased if the patient tolerates the initial rate well.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 0.4 to 0.8 g/kg (approx. 1 to 4 g) | Every 3 to 4 weeks for replacement therapy | Administered strictly under clinical supervision in a hospital setting. Start infusion at a very slow rate. |
| 5-7 kg | 2 to 5.6 g (based on 0.4 to 0.8 g/kg) | Every 3 to 4 weeks | Doses up to 2 g/kg may be used for immunomodulation, divided over 2 to 5 days. Ensure adequate hydration. |
| 8-10 kg | 3.2 to 8 g (based on 0.4 to 0.8 g/kg) | Every 3 to 4 weeks | Monitor renal function and urine output closely during therapy. |
| 11-15 kg | 4.4 to 12 g (based on 0.4 to 0.8 g/kg) | Every 3 to 4 weeks | Monitor vital signs continuously during infusion and for at least 20 minutes after completion. |
| 16-20 kg | 6.4 to 16 g (based on 0.4 to 0.8 g/kg) | Every 3 to 4 weeks | Infusion rate can be gradually increased if the patient tolerates the initial rate well. |
Formulation
Purpose
Used for replacement therapy in patients with primary and secondary immunodeficiency diseases, and for immunomodulation in conditions like idiopathic thrombocytopenic purpura (ITP), Guillain-Barré syndrome, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN).
Generic Name
Human Normal Immunoglobulin (IVIg)Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.